创模生物科技(北京)有限公司

CN / En

New Drug Development Services

New Drug Development Services

All categories
/
Syngeneic models

Syngeneic models

Description:Homologous model
Description:Homologous model
Information

Syngeneic mouse models involve the use of immunocompetent mice to establish syngeneic transplantation models of murine-origin tumors. Due to the completely natural immune system in these mice, they serve as an ideal choice for testing various immunotherapies. This model allows for the evaluation of immune responses that closely resemble clinical scenarios.

 

● Our platform boasts access to over 60 different tumor cell lines, covering a wide spectrum of cancer types and subtypes. This diverse collection enables you to select the most suitable cell lines for your research, ensuring relevance to your specific area of study.

 

● Our team of researchers possesses extensive operational experience, ensuring high-quality execution of experiments.

 

● Our cells undergo internal validation to guarantee their quality and stability, providing a reliable foundation for research.

 

● Our platform boasts strong immunological analysis capabilities with a ready stock of various mouse flow cytometry antibodies. We can perform PK/PD analyses at any time to support pharmacological efficacy experiments.

 

● Our scientific team is composed of PhDs with extensive industry experience. They are dedicated to providing scientific support for every project. Whether it's designing experiments, troubleshooting, or offering guidance on data interpretation, our experts are here to ensure your research is on the right track.

 

● We offer tailored experimental support, designing experiments according to your research needs to ensure optimized experimental protocols that align with your specific objectives.

 

Types Cell Line Name Synonyms Disease (English) Species of origin
Hemato>Leukemia  C1498   Mouse leukemia Mus musculus>C57BL/6
Solid>Digestive system>Digestive tract>Colon MC-38 MCA-38; MCA 38; MCA38; MC38; Mouse Colon 38; Murine Carcinoma-38; Colon 38; Colon-38; Colon38; C38 Mouse colon adenocarcinoma Mus musculus>C57BL/6
Solid>Skin B16-F10 B16/F10; B16 F10; B16F10; B16 melanoma F10 Mouse melanoma Mus musculus>C57BL/6
Solid>Male reproductory system>Testis MLTC-1 mLTC-1; Murine Leydig Tumor Cell line-1 Mouse leydig cell tumor Mus musculus>C57BL/6
Solid>Female reproductory system>Ovary ID8-luc ID8luc2   Mus musculus>C57BL/6
Solid>Digestive system>Digestive tract>Stomach MFC Mouse Forestomach Carcinoma Mouse gastric carcinoma Mus musculus
Solid>Digestive system>Digestive tract>Colorectal MC38-C17 MC38-C17 Mouse colon adenocarcinoma Mus musculus>C57BL/6
Solid>Digestive system>Digestive tract>Colorectal MC38-FR MC38-FR Mouse colon adenocarcinoma Mus musculus>C57BL/6
Solid>Digestive system>Digestive tract>Colorectal MC38(2) MC38(2) Mouse colon adenocarcinoma Mus musculus>C57BL/6
Solid>Digestive system>Digestive tract>Colorectal CT26 CT-26; CT 26; Colon Tumor 26 Mouse colon adenocarcinoma Mus musculus>BALB/c
Solid>Digestive system>Digestive tract>Colorectal CT26-C17 CT26-C17 Mouse colon adenocarcinoma Mus musculus>BALB/c
Solid>Digestive system>Liver and billiary tract>Hepatic Hepa1-6 HEPA 1-6; Hepa-1-6; Hepa1-6 Hepatocellular carcinoma of the mouse Mus musculus>C57L
Solid>Digestive system>Liver and billiary tract>Hepatic Hepa-1c1c7 Hepa 1c1c7; Hepa1c1c7; Hepa 1-clc7 Hepatocellular carcinoma of the mouse Mus musculus>C57L

 

In this study, we tested an immunomodulatory agent based on traditional herbal medicine. In the MC38 cell line, this treatment regimen demonstrated efficacy similar to PD-1 therapy. However, TIL analysis revealed that the mechanism of action of this treatment differs from that of PD-1 therapy. Specifically, it reduces tumor burden in tumor-bearing mice by significantly decreasing M2 macrophage infiltration within TILs.

 

Case

Keyword: Homologous model

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司